MA38060A1 - Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation - Google Patents
Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisationInfo
- Publication number
- MA38060A1 MA38060A1 MA38060A MA38060A MA38060A1 MA 38060 A1 MA38060 A1 MA 38060A1 MA 38060 A MA38060 A MA 38060A MA 38060 A MA38060 A MA 38060A MA 38060 A1 MA38060 A1 MA 38060A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridincarboxamides
- amidazo
- amino
- substituted
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La présente invention concerne de nouveaux imidazo[1,2-a]pyridin-3-carboxamides substitués, leurs procédés de production, leur utilisation seuls ou en association aux fins de traitement et/ou de prévention de maladies ainsi que leur utilisation pour la production de médicaments aux fins de traitement et/ou de prévention de maladies, notamment de traitement et/ou de prévention de maladies cardiovasculaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12191201 | 2012-11-05 | ||
PCT/EP2013/072891 WO2014068099A1 (fr) | 2012-11-05 | 2013-11-04 | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38060A1 true MA38060A1 (fr) | 2016-10-31 |
Family
ID=47088758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38060A MA38060A1 (fr) | 2012-11-05 | 2015-05-04 | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation |
Country Status (2)
Country | Link |
---|---|
US (1) | US9126998B2 (fr) |
MA (1) | MA38060A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624214B2 (en) * | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
JP2016522214A (ja) | 2013-06-04 | 2016-07-28 | バイエル・ファルマ・アクティエンゲゼルシャフト | 3−アリール−置換イミダゾ[1,2−a]ピリジンおよびその使用 |
EP3030562B1 (fr) * | 2013-08-08 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Pyrazolo[1,5-a]pyridine-3-carboxamides substitués et leur utilisation |
WO2015082411A1 (fr) * | 2013-12-05 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridine-3-carboxamides aryl et hétéroaryl substitués et leur utilisation |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
CN106459090A (zh) | 2014-02-19 | 2017-02-22 | 拜耳制药股份公司 | 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶 |
CN106715426A (zh) | 2014-03-21 | 2017-05-24 | 拜耳医药股份有限公司 | 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途 |
CN106470995A (zh) * | 2014-05-02 | 2017-03-01 | 拜耳医药股份有限公司 | 用于治疗心血管疾病的作为可溶性鸟苷酸环化酶刺激物的咪唑并[1,2‑a]吡啶类 |
EP3137463A1 (fr) * | 2014-05-02 | 2017-03-08 | Bayer Pharma Aktiengesellschaft | Énantiomères du n-(2-amino-5-fluor-2-méthylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-méthylimidazo[1,2-a]pyridine-3-carboxamide et de ses dérivés difluorés et trifluorés pour traiter des maladies cardiovasculaires |
WO2015165970A1 (fr) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridine carboxamides substitués par chlore en position 6 et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble |
WO2016087343A1 (fr) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridines à substitution hétéroaryle et leur utilisation |
EP3227286B1 (fr) | 2014-12-02 | 2018-12-26 | Bayer Pharma Aktiengesellschaft | Pyrazolo[1,5-a]pyridines et imidazo[1,2-a]pyrazines substituées et leur utilisation |
CA2975639A1 (fr) | 2015-02-05 | 2016-08-11 | Bayer Pharma Aktiengesellschaft | Pyrazolo[1,5-a]pyridine-3-carboxamides substitues et leur utilisation |
CA2989740C (fr) | 2015-07-23 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Stimulateurs et/ou activateurs de la guanylate-cyclase soluble (sgc) en association avec un inhibiteur de l'endopeptidase neutre (inhibiteur nep) et/ou des antagonistes d'une angiotensine ii et leur utilisation |
MX2018007152A (es) | 2015-12-14 | 2018-08-15 | Ironwood Pharmaceuticals Inc | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. |
WO2018111795A2 (fr) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ221996A (en) | 1986-10-07 | 1989-08-29 | Yamanouchi Pharma Co Ltd | Imidazo-pyridine derivatives and pharmaceutical compositions |
SE8704248D0 (sv) | 1987-10-30 | 1987-10-30 | Haessle Ab | Medical use |
JP2643274B2 (ja) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | イミダゾ〔1,2−a〕ピリジン誘導体 |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
WO1996034866A1 (fr) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Derives de l'imidazo 1,2-a pyridine et de l'imidazo 1,2-a pyridezine et leur utilisation en tant qu'inhibiteurs de la resorption osseuse |
CA2196263C (fr) | 1996-02-09 | 2004-10-26 | Barry Jackson | Methode de preparation de sels de 4-oxo-imidazolinium |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
CA2407573C (fr) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Derives d'imidazopyridine |
DE502005003491D1 (de) | 2004-08-02 | 2008-05-08 | Sanol Arznei Schwarz Gmbh | Carboxamide des indolizins und seiner aza- und diazaderivate |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
JP5079011B2 (ja) | 2006-10-19 | 2012-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11β−HSD1阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体 |
DE102006054562A1 (de) | 2006-11-20 | 2008-05-21 | Bayer Healthcare Ag | Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion |
WO2008082490A2 (fr) | 2006-12-20 | 2008-07-10 | Schering Corporation | Nouveaux inhibiteurs de jnk |
WO2008134553A1 (fr) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Procédés de traitement de maladies associées aux canaux sodiques au moyen de composés bicycliques |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
CA2793086C (fr) | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Composes d'imidazo[1,2-a]pyridine substitue et leur utilisation pour le traitement d'infections bacteriennes |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
EP2716642B1 (fr) | 2011-05-30 | 2016-07-20 | Astellas Pharma Inc. | Composé imidazopyridine |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
-
2013
- 2013-03-07 US US13/789,655 patent/US9126998B2/en active Active
-
2015
- 2015-05-04 MA MA38060A patent/MA38060A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US9126998B2 (en) | 2015-09-08 |
US20140128372A1 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
MA35844B1 (fr) | Pyrimidines et triazines annelées substituées et leur utilisation | |
MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
PH12019502809A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
MA42376B1 (fr) | Dérivés d'oxopyridine substitués | |
PH12017501481B1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
PH12015500988A1 (en) | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
MX2019010709A (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
WO2012088266A3 (fr) | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 | |
MA33123B1 (fr) | 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation | |
MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
MA34019B1 (fr) | Aryltriazolone liée à un bis-aryle et son utilisation | |
WO2013104598A3 (fr) | Imidazoles et pyrazoles annelés substitués et leur utilisation | |
MA35039B1 (fr) | Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation | |
MY172308A (en) | Bicyclic pyrazinone derivatives | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
MX2013002261A (es) | N-fenetiltriazolonacetamidas sustituidas y su uso. | |
MA37928A1 (fr) | Tri(hétéro)arylpyrazoles et leur utilisation | |
MA38637A1 (fr) | Benzoxazoles substitués | |
MA38950A1 (fr) | Thiénouracile-carboxamides cycliques et utilisation associée | |
MA37780B1 (fr) | Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation |